As a cancer epidemiologist, Dr. Sarah C. Markt focuses on integrating molecular, lifestyle, and clinical epidemiology to study risk factors for initiation and progression of genitourinary cancers, with the goal of translating findings into cancer prevention. Her work encompasses a number of studies including research on circadian rhythm disruption as a risk factor for prostate cancer, and the effects of a physical activity intervention on men with prostate cancer. She also is researching the clinical utility of using tumor genomic markers for genitourinary cancers. In addition to this work, she directs the disease follow-up of men with bladder cancer in a 50,000 subject longitudinal cohort study. Finally, she co-directs a testicular cancer patient database at the Dana-Farber Cancer Institute (DFCI). In addition to her own research, she serves as a research mentor to undergraduate and graduate students, and clinical fellows.
My research involves integrating molecular, lifestyle and clinical epidemiology to study risk factors for initiation and progression of cancer, with the primary goal to translate research findings into direct application for primary and secondary cancer prevention. A major area of my research focus is in investigating circadian rhythm disruption as a risk factor for cancer, and particularly for risk of advanced prostate cancer. I am also interested in understanding the molecular basis for tumor progression and the clinical utility of utilizing genomic markers for cancer outcomes, with a particular focus on prostate, testicular and bladder cancer. Another area of my research focus is in developing lifestyle interventions (e.g. physical activity) to enhance the efficacy of therapeutic interventions, ameliorate treatment-related effects, and improve overall health and quality of life among cancer patients.
- Allott, EH, Ebot, EM, Stopsack, KH, Gonzalez-Feliciano, AG, Markt, SC, Wilson, KM, Ahearn, TU, Gerke, TA, Downer, MK, Rider, JR, Freedland, SJ, Lotan, TL, Kantoff, PW, Platz, EA, Loda, M, Stampfer, MJ, Giovannucci, E, Sweeney, CJ, Finn, SP, Mucci, LA. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin. Cancer Res. 2020; 26 (5): 1086-1093. PubMed PMID:31754047 PubMed Central PMC7056554.
- Dickerman, BA, Torfadottir, JE, Valdimarsdottir, UA, Giovannucci, E, Wilson, KM, Aspelund, T, Tryggvadottir, L, Sigurdardottir, LG, Harris, TB, Launer, LJ, Gudnason, V, Markt, SC, Mucci, LA. Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study. Cancer 2019; 125 (16): 2877-2885. PubMed PMID:31179538 PubMed Central PMC6663585.
- McGregor, BA, Miller, RE, O'Donnell, E, Albiges, LK, Sweeney, CJ, Markt, SC. Body Mass Index and Outcomes in Germ-Cell Tumors. Clin Genitourin Cancer 2019; 17 (4): 283-290. PubMed PMID:31129146 .
- Abufaraj, M, Tabung, FK, Shariat, SF, Moschini, M, Devore, E, Papantoniou, K, Yang, L, Strohmaier, S, Rohrer, F, Markt, SC, Zhang, X, Giovannucci, E, Schernhammer, E. Association between Inflammatory Potential of Diet and Bladder Cancer Risk: Results of 3 United States Prospective Cohort Studies. J. Urol. 2019; 202 (3): 484-489. PubMed PMID:31009297 .
- AlDubayan, SH, Pyle, LC, Gamulin, M, Kulis, T, Moore, ND, Taylor-Weiner, A, Hamid, AA, Reardon, B, Wubbenhorst, B, Godse, R, Vaughn, DJ, Jacobs, LA, Meien, S, Grgic, M, Kastelan, Z, Markt, SC, Damrauer, SM, Rader, DJ, Kember, RL, Loud, JT, Kanetsky, PA, Greene, MH, Sweeney, CJ, Kubisch, C, Nathanson, KL, Van Allen, EM, Stewart, DR, Lessel, D, Regeneron Genetics Center (RGC) Research Team. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol 2019; 5 (4): 514-522. PubMed PMID:30676620 PubMed Central PMC6459214.
- Hamid, AA, Markt, SC, Vicier, C, McDermott, K, Richardson, P, Ho, VT, Sweeney, CJ. Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer 2019; 17 (1): 58-64.e1. PubMed PMID:30309761 .
- Robinson, CD, Gonzalez-Feliciano, A, Mucci, LA, Markt, SC. Smoking cessation among men following cancer diagnosis: a matched cohort study. J Cancer Surviv 2018; 12 (6): 786-793. PubMed PMID:30302603 .
- Pernar, CH, Ebot, EM, Pettersson, A, Graff, RE, Giunchi, F, Ahearn, TU, Gonzalez-Feliciano, AG, Markt, SC, Wilson, KM, Stopsack, KH, Gazeeva, E, Lis, RT, Parmigiani, G, Rimm, EB, Finn, SP, Giovannucci, EL, Fiorentino, M, Mucci, LA. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. Eur. Urol. 2019; 76 (1): 33-40. PubMed PMID:30301696 PubMed Central PMC6451672.
- Tsang, SH, Peisch, SF, Rowan, B, Markt, SC, Gonzalez-Feliciano, AG, Sutcliffe, S, Platz, EA, Mucci, LA, Ebot, EM. Association between Trichomonas vaginalis and prostate cancer mortality. Int. J. Cancer 2019; 144 (10): 2377-2380. PubMed PMID:30242839 PubMed Central PMC6430694.
- Preston, MA, Gerke, T, Carlsson, SV, Signorello, L, Sjoberg, DD, Markt, SC, Kibel, AS, Trinh, QD, Steinwandel, M, Blot, W, Vickers, AJ, Lilja, H, Mucci, LA, Wilson, KM. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur. Urol. 2019; 75 (3): 399-407. PubMed PMID:30237027 PubMed Central PMC6390280.
Metrics from Web of Science/publons and Scopus/SciVal:
- H-index: 10
- Total publications: 39
- Total citations: 265
- Publications in top-tier journals: 50%
- Collaborative publishing national/international: 32%/68%
Residencies, Internships and Fellowships
Contributions to science:
- Investigated the role of a urinary biomarker (melatonin), genetic variation and questionnaire data on sleep duration and disruption in prostate cancer risk and progression.
- Through collaboration, investigated genetic variation and aggressive prostate cancer risk utilizing a candidate gene approach. Also found single nucleotide polymorphisms in circadian related genes were associated with risk or fatal prostate cancer.
- Investigated modifiable lifestyle factors in early-, mid-, and later-life, for risk of advanced and lethal prostate cancers using cohorts nationally and internationally.
- Investigated through collaboration risk factors for progression of testicular germ cell tumors using a clinical testicular cancer patient database and publicly available datasets, including evaluating health disparities among this young patient population.
- Case Comprehensive Cancer Center ACS Institutional Grant Pilot Award: Exploring molecular mechanisms of circadian disruption and prostate cancer
- NIH/NCI R01: Molecular origins and evolution to chemoresistance in germ cell tumors
- NCI/DFCI Prostate Cancer SPORE Career Development Award: Spore Career Award: Circadian rhythm disruption and advanced prostate cancer
- NIH/NCI R01: Circadian Disruption and Risk of Prostate Cancer in a Multiethnic Cohort